Record Nr.	UNINA9910437811403321
Autore	Mizuhara Tsukasa
Titolo	Development of Novel Anti-HIV Pyrimidobenzothiazine Derivatives / / by Tsukasa Mizuhara
Pubbl/distr/stampa	Tokyo : , : Springer Japan : , : Imprint : Springer, , 2013
ISBN	4-431-54445-3
Edizione	[1st ed. 2013.]
Descrizione fisica	1 online resource (157 p.)
Collana	Springer Theses, Recognizing Outstanding Ph.D. Research, , 2190- 5053
Disciplina	616.9792
Soggetti	Organic chemistry Pharmaceutical technology Medicinal chemistry Virology Organic Chemistry Pharmaceutical Sciences/Technology Medicinal Chemistry
Lingua di pubblicazione	Inglese
Formato	Materiale a stampa
Livello bibliografico	Monografia
Note generali	Description based upon print version of record.
Nota di bibliografia	Includes bibliographical references.
Nota di contenuto	Introduction Development of Divergent Synthetic Methods of Pyrimidobenzothiazine and Related Tricyclic Heterocycles Structure– Activity Relationship Study of PD 404182 Derivatives for the Highly Potent Anti-HIV Agents Design and Synthesis of Photoaffinity Probes and Their Application to Target Identification Study of PD 404182 Conclusion.
Sommario/riassunto	The author successfully developed novel anti-HIV PD 404182 derivatives that exhibited submicromolar inhibitory activity against both HIV-1 and HIV-2. His thesis is in three parts. The first part expounds efficient methods for the synthesis of tricyclic heterocycles related to PD 404182 based on the sp2-carbonheteroatom bond formations. Starting from arene or haloarene, C-O, C-N, or C-S bonds were formed by simply changing the reactants. These synthetic methods provide powerful approaches for the divergent preparation of pyrimido-benzoxazine, -quinazoline, or -benzothiazine derivatives. The second part explains SAR studies of PD 404182 for the

1.

development of anti-HIV agents. Through optimization studies of the central 1,3-thiazin-2-imine core, the benzene and cyclic amidine ring parts, 3-fold more potent inhibitors were obtained compared with the lead compound. The author also reveals by a time-of-drug-addition experiment that PD 404182 derivatives impaired HIV replication at the binding or fusion stage. The third part of the thesis elucidates the development of photoaffinity probes for the target identification of PD 404182. By the photolabeling experiment of HIV-1-infected H9 cells using these probes, the author detected proteins specifically bound to PD 404182. These new anti-HIV agents may be promising agents for anti-HIV therapy because their mechanisms of action differ from those of the currently approved anti-HIV agents.